US2006115864A1PendingUtilityA1

Assays for identifying ubiquitin agents and for identifying agents that modify the activity of ubiquitin agents

Assignee: RIGEL PHARMACEUTICALS INCPriority: Apr 3, 2000Filed: Mar 25, 2005Published: Jun 1, 2006
Est. expiryApr 3, 2020(expired)· nominal 20-yr term from priority
G01N 33/542Y10T436/255G01N 33/6842G01N 2500/02G01N 2500/00G01N 2333/9015C12Q 1/25G01N 33/68Y10S436/805G01N 33/5008C12Q 1/37G01N 2500/04G01N 33/573
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Provided are methods and compositions for assaying for ubiquitin agents that are enzymatic components of ubiquitin-mediated proteolysis and, more particularly, methods and compositions for assaying for agents that modulate the activity of such ubiquitin agents.

Claims

exact text as granted — not AI-modified
1 . A method of assaying for an agent that modulates the attachment of a ubiquitin moiety to at least one ubiquitin agent, said method comprising: 
 a) combining: 
 i) a first ubiquitin agent;  
 ii) a candidate agent; and  
 iii) a ubiquitin moiety; and  
   b) assaying for the attachment of said ubiquitin moiety to said first agent.    
     
     
         2 . The method according to  claim 1 , wherein said first ubiquitin agent is an ubiquitin activating agent.  
     
     
         3 . The method according to  claim 2 , wherein said ubiquitin activating agent is an E1.  
     
     
         4 . The method according to  claim 1 , further comprising including a second ubiquitin agent in said combining step.  
     
     
         5 . The method according to  claim 4 , wherein said first agent is a ubiquitin conjugating agent and said second agent is a ubiquitin activating agent.  
     
     
         6 . The method according to  claim 5 , wherein said ubiquitin conjugating agent is an E2 and said ubiquitin activating agent is an E1.  
     
     
         7 . The method according to  claim 4 , wherein said first agent is a ubiquitin ligating agent and said second agent is a ubiquitin conjugating agent comprising said ubiquitin moiety.  
     
     
         8 . The method according to  claim 7 , wherein said ubiquitin ligating agent is an E3 and said ubiquitin conjugating agent is an E2 comprising said ubiquitin moiety.  
     
     
         9 . The method according to  claim 5 , wherein said ubiquitin conjugating agent is an E2 and said ubiquitin activating agent is an E1 comprising said ubiquitin moiety.  
     
     
         10 . The method according to  claim 9  further comprising including a third ubiquitin agent in said combining step.  
     
     
         11 . The method according to  claim 10 , wherein said third agent is a ubiquitin ligating agent.  
     
     
         12 . The method according to  claim 11 , wherein said ubiquitin ligating agent is an E3.  
     
     
         13 . The method according to  claim 1 , wherein said first ubiquitin agent is attached to a solid support.  
     
     
         14 . The method according to claims  4 , wherein said second ubiquitin agent is attached to a solid support.  
     
     
         15 . The method according to  claim 7 , wherein said first ubiquitin agent is attached to a solid support.  
     
     
         16 . The method according to any of claims  13 ,  14 , and  15 , wherein said solid support is a microtiter plate.  
     
     
         17 . The method according to any of claims  13 ,  14 , and  15 , wherein said solid support is a bead.  
     
     
         18 . The method according to claims  1  or  7 , wherein said first agent comprises a tag.  
     
     
         19 . The method according to  claim 4 , wherein said second agent comprises a tag.  
     
     
         20 . The method according to any of claims  1 ,  4 , and  7 , wherein said ubiquitin moiety comprises a tag.  
     
     
         21 . The method according to claims  1  or  7 , wherein said first agent comprises an attachment tag.  
     
     
         22 . The method according to  claim 4 , wherein said second agent comprises an attachment tag.  
     
     
         23 . The method according to claims  1  or  7 , wherein said first agent comprises a label  
     
     
         24 . The method according to  claim 4 , wherein said second agent comprises a label.  
     
     
         25 . The method according to claims  1  or  7 , wherein said first agent comprises an epitope tag.  
     
     
         26 . The method according to  claim 4 , wherein said second agent comprises an epitope tag.  
     
     
         27 . The method according to any of claims  1 ,  4 , and  7 , wherein at least a first and a second ubiquitin moiety is used, wherein said first and second ubiquitin moiety moieties comprise different fluorescent labels, and wherein said labels form a fluorescence resonance energy transfer (FRET) pair.  
     
     
         28 . A method of assaying for an agent that modulates the attachment of a ubiquitin moiety to at least one ubiquitin agent, said method comprising: 
 a) combining: 
 i) a first ubiquitin agent comprising a ubiquitin ligating agent;  
 ii) a second ubiquitin agent;  
 iii) a candidate agent;  
 iv) a ubiquitin moiety; and  
 v) a target protein; and  
 assaying for the attachment of said ubiquitin moiety to said first agent.  
   
     
     
         29 . The method according to  claim 28 , wherein said second agent is a ubiquitin conjugating agent comprising said ubiquitin moiety.  
     
     
         30 . The method according to  claim 28  further comprising including a third ubiquitin agent in said combining step, wherein said third agent is a ubiquitin activating agent; wherein said substrate and said ubiquitin moiety comprise different fluorescent labels, and wherein said labels form a fluorescence resonance energy transfer (FRET) pair.  
     
     
         31 . The method according to  claim 1  or  28 , wherein said ubiquitin moiety is a mammalian ubiquitin moiety.  
     
     
         32 . The method according to  claim 28 , wherein said ubiquitin moiety comprises a label.  
     
     
         33 . The method according to  claim 28 , wherein said label comprises an epitope tag.

Join the waitlist — get patent alerts

Track US2006115864A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.